摘要
目的探讨依帕司他对早期2型糖尿病肾病尿白蛋白排泄率(UAE)的影响。方法36例2型早期糖尿病肾病患者在原来治疗的基础上,予依帕司他150 mg qd治疗16个月,并在治疗前后测患者UAE、血压、体重指数(BMI)、血清肌酐清除率(Ccr)及血糖、血脂。结果依帕司他治疗前后患者血糖、血脂、血压、BMI、Ccr没有显著变化(P>0.05),治疗后UAE比治疗前UAE显著下降(P<0.01)。结论依帕司他可以阻抑早期糖尿病肾病的病情发展。
Objective To investigate the effect of epalrestat on urinary albumin excretion （UAE） in patients with type-2 diabetics with early diabetic nephropathy. Methods 36 patients with type-2 diabetics with early diabetic nephropathy were administered with epalrestat 150 mg once daily for sixteen months on the basis of prior treatment of type 2 diabetic nephropathy, UAE, body mass index （BMI）, blood pressure, blood fat level, creatinine clearance rates （Ccr） , and blood glucose were determined at baseline and in the end of treatment period. Results Blood glucose, blood fat, blood pressure, BMI and Ccr remained stable before and after treatment with epalrestat（P 〉 0.05 ）, and a significant decrease in UAE was observed before and after treatment （ P 〈 0. 01 ）. Conclusion Epalrestat could prevent the progression of early diabetic nephropathy in patients with type II diabetics.
出处
《广东药学院学报》
CAS
2009年第1期94-96,共3页
Academic Journal of Guangdong College of Pharmacy
